CHRM3 gene variation is associated with decreased acute insulin secretion and increased risk for early-onset type 2 diabetes in Pima Indians

Diabetes. 2006 Dec;55(12):3625-9. doi: 10.2337/db06-0379.

Abstract

The muscarinic acetylcholine receptor subtype M3 (CHRM3) gene is expressed in islet beta-cells and has a role in stimulating insulin secretion; therefore, CHRM3 was analyzed as a candidate gene for type 2 diabetes in Pima Indians. Ten variants were genotyped in a family-based sample (n = 1,037), and 1 variant (rs3738435) located in the 5' untranslated region of an alternative transcript was found to be modestly associated with both early-onset type 2 diabetes and the acute insulin response in a small subset of these subjects. To better assess whether this variant has a role in acute insulin secretion, which could affect risk for early-onset type 2 diabetes, rs3738435 was genotyped in a larger group of normal glucose-tolerant Pima Indians who had measures of acute insulin secretion (n = 282) and a larger case-control group of Pima Indians selected for early-onset type 2 diabetes (n = 348 case subjects with age of onset <25 years; n = 392 nondiabetic control subjects aged >45 years). Genotyping in these larger sets of subjects confirmed that the C allele of rs3738435 was associated with a reduced acute insulin response (adjusted P = 0.00006) and was also modestly associated with increased risk of early-onset type 2 diabetes (adjusted P = 0.02).

Publication types

  • Research Support, N.I.H., Intramural

MeSH terms

  • Adipose Tissue / anatomy & histology
  • Adult
  • Age of Onset
  • Aged
  • Arizona
  • Diabetes Mellitus, Type 2 / epidemiology
  • Diabetes Mellitus, Type 2 / genetics*
  • Gene Expression Profiling
  • Genetic Variation*
  • Glucose Tolerance Test
  • Humans
  • Indians, North American
  • Insulin / metabolism*
  • Insulin Secretion
  • Polymerase Chain Reaction
  • Receptor, Muscarinic M3 / genetics*
  • Risk Factors

Substances

  • Insulin
  • Receptor, Muscarinic M3